Results 51 to 60 of about 4,006,149 (207)

IDO1 is an Integral Mediator of Inflammatory Neovascularization [PDF]

, 2016
The immune tolerogenic effects of IDO1 (indoleamine 2,3-dioxygenase 1) have been well documented and genetic studies in mice have clearly established the significance of IDO1 in tumor promotion.
Smith, Courtney, DuHadaway, James B., Muller, Alexander J., Mondal, Arpita, Prendergast, George C., Bravo-Nuevo, Arturo, Sutanto-Ward, Erika   +6 more
core   +3 more sources

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past

Journal of Experimental & Clinical Cancer Research, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-containing enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metabolism, which plays an important role in immunity and neuronal function.
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger, Qing Yang   +8 more
doaj   +1 more source

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal of Immunotherapy for Cancer, 2018
BackgroundIndoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer.
Asha Nayak-Kapoor, Zhonglin Hao, R. Sadek, Robin Dobbins, L. Marshall, N. Vahanian, W. J. Ramsey, E. Kennedy, M. Mautino, C. Link, R. Lin, S. Royer-Joo, Xiaorong Liang, L. Salphati, K. Morrissey, S. Mahrus, B. McCall, A. Pirzkall, D. Munn, J. Janik, S. Khleif   +20 more
semanticscholar   +1 more source

Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening

Frontiers in Pharmacology, 2018
Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellular monomeric heme-containing enzyme that catalyzes the first and the rate limiting step in catabolism of tryptophan via the kynurenine (KYN) pathway, which plays a significant role in the ...
Guoqing Zhang, Guoqing Zhang, Jing Xing, Jing Xing, Yulan Wang, Yulan Wang, Lihao Wang, Yan Ye, Yan Ye, Dong Lu, Dong Lu, Jihui Zhao, Jihui Zhao, Xiaomin Luo, Mingyue Zheng, Shiying Yan   +15 more
doaj   +1 more source

Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis

Advanced Science, EarlyView.
A thermo‐responsive rectal delivery platform integrating probiotic‐derived extracellular vesicles within a hyaluronic acid‐based copolymer enables localized and sustained therapy for ulcerative colitis. The formulation effectively suppresses inflammation, promotes macrophage polarization toward a regenerative phenotype, restores epithelial barrier ...
Ayushi Mairal, Ubaid Tariq, Shreya Mehrotra, Saravanan Matheshwaran, Jan Marsal, Ashok Kumar   +5 more
wiley   +1 more source

Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity

Advanced Science, EarlyView.
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang, Xiaowei Cai, Xiaoyan Zhong, Tian Qiu, Qinwei Lu, Jiahao Qin, Fei Gong, Yecheng Huang, Chenyu Jiang, Youdong Chen, Yuan Cheng, Liang Cheng   +11 more
wiley   +1 more source

IDO1 Inhibitor KHK2455

Definitions, 2020
An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of ...

semanticscholar   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages

, 2023
Xiao Chen,1,2 Jie Yao,1 Meng-Yu Zhang,1 Rui Li,1 Xiao Liu,1 Yi-Qing Qu1 1Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 2Department of Respiratory Medicine, Tai’an City Central
Liu X, Yao J, Zhang MY, Chen X, Li R, Qu YQ   +5 more
core  

Companies Scaling Back IDO1 Inhibitor Trials.

Cancer Discovery, 2018
Based on negative results of the ECHO-301 trial in melanoma, as well as in the pancreatic cancer cohort of ECHO-203, Incyte halted several trials of its IDO inhibitor epacadostat. Other companies, including NewLink Genetics and Bristol-Myers Squibb, also

semanticscholar   +1 more source